Skip to content

24/7 dementia helpline 800-272-3900

Dementia Today

Molecular modeling of novel potent agents for treating Alzheimer’s disease

Dementia TodayPublished June 11, 20154 min read

Key points

  • Alzheimer’s disease (AD), a severe form of dementia among aged individuals, is caused by accumulation of amyloid-beta (Aβ) peptides in the brain.
  • Currently, Toyohashi Tech researchers in cooperation with a researcher at the National Academy of Sciences in Ukraine, proposed new agents for protecting the cleavage site of APP from attack by γ-secretase, based on results evaluated by their state-of-the-art molecular simulations.
  • Journal of Molecular Graphics and Modeling, 50, 113-124, 2014; Yano et al.
  • Our developed state-of-the-art molecular simulations can be applied to the study of other vital proteins that play important roles in the pathogenesis of numerous diseases.

Alzheimer’s disease (AD), a severe form of dementia among aged individuals, is caused by accumulation of amyloid-beta (Aβ) peptides in the brain. Numerous types of agents have been developed to suppress the production of Aβ, by inhibiting the secretase-mediated cleavage of amyloid precursor protein (APP) into Aβ peptides.

However, because the secretases also play important roles in the production of vital proteins for the human body, inhibitors of the secretases have increased risk for side effects.

Currently, Toyohashi Tech researchers in cooperation with a researcher at the National Academy of Sciences in Ukraine, proposed new agents for protecting the cleavage site of APP from attack by γ-secretase, based on results evaluated by their state-of-the-art molecular simulations.

They investigated the specific interactions between a short APP peptide and curcumin derivatives for the first time worldwide, using protein-ligand docking as well as ab initio molecular simulations. Curcumin is a constituent of turmeric, which is a popular yellow spice in Indian cuisine. The simulated results elucidated the specific curcumin derivative and showed that it bound more strongly to APP and inhibited the binding of secretase to APP more than the other derivatives did . Moreover, some novel curcumin derivatives were proposed as potent inhibitors of Aβ peptide production. These derivatives are novel agents for suppressing AD and are proposed based on the novel concept of preventing APP cleavage. However, this does not imply that the consumption of Indian cuisine suppresses AD.

The first author, graduate student Hiromi Ishimura said, “We have also been studying the aggregation mechanism of Aβ peptides by using molecular dynamics simulations (Okamoto et al. Journal of Molecular Graphics and Modeling, 50, 113-124, 2014; Yano et al. Chemical Physics Letters, 595-596, 242-249, 2014). By combining the present ab initio molecular simulation and the molecular dynamics simulations, we will be able to elucidate the mechanism and propose potent inhibitors for suppressing the aggregation of Aβ peptides. These inhibitors are used as a therapeutic agent for ADs.”

Associate Professor Noriyuki Kurita said, “Our present molecular simulations elucidated that curcumin can bind APP and inhibit the cleavage of APP by secretase. Curcumin is a natural product contained in the root of Curcumae Rhizoma. In the laboratory of our collaborator at National Academy of Sciences in Ukraine, our proposed curcumin derivatives will be synthesized and theirs effects on experimental animals with ADs will be investigated.”

Our developed state-of-the-art molecular simulations can be applied to the study of other vital proteins that play important roles in the pathogenesis of numerous diseases. In developing countries such as Ukraine, tuberculosis (TB), which is a severe infection caused by Mycobacterium tuberculosis is prevalent. In fact, about 9 million people are infected with TB worldwide and 1.5 million died from this infection in 2013. Therefore, the urgent development of novel drugs for TB is necessary. We are currently performing molecular simulations to propose novel potent inhibitors of a protein that reduces the blood level of anti-tubercular as well as anti-human immunodeficiency virus (HIV) agents. This collaborative study with Ukrainian researchers will be applied to the “Science and Technology Research Partnership for Sustainable Development Project” organized by Japan Science and Technology Agency (JST) and Japan International Cooperation Agency (JICA) in 2015.

###

References:

Authors: Hiromi Ishimura1, Ryushi Kadoya1, Tomoya Suzuki1, Takeru Murakawa1, Sergiy Shulga2, and Noriyuki Kurita1,*.

Title of original paper: Specific interactions between amyloid-β peptide and curcumin derivatives: ab initio molecular simulations.

Journal, volume, pages, and year: Chemical Physics Letters, 633, 139-145, 2015 .

Digital Object Identifier (DOI): 10.1016/j.cplett.2015.05.023

Affiliations:

1 Department of Computer Science and Engineering, Toyohashi University of Technology, Toyohashi, 441-8580, Japan,
2 Institute for Food Biotechnology and Genomics, National Academy of Sciences of Ukraine, Kyiv, Ukraine

Further information

Toyohashi University of Technology
1-1 Hibarigaoka, Tempaku
Toyohashi, Aichi Prefecture, 441-8580, JAPAN
Inquiries: Committee for Public Relations
E-mail: press@office.tut.ac.jp

The content on this site is for information only and is not a substitute for professional medical advice, diagnosis or treatment. If a person with dementia is missing, injured or in danger, call 911 or your local emergency number.

Filed underDementia News

Worried about memory changes?

Normal aging, or an early warning sign?

Ten common changes, each set beside what is typical with age. Tick what you have noticed and see what to do next.

Open the 10-sign checklist

Getting help

Sudden changes are not just the dementia.

Dementia usually changes slowly. A sharp change over hours or days can mean an infection, delirium, a stroke or a medication problem, and needs a doctor the same day. Call 911 or your local emergency number if you see any of these:

  • Confusion that comes on suddenly, over hours or days
  • Face drooping, arm weakness or slurred speech
  • A fall, a head injury or new severe pain
  • Very drowsy or hard to wake

The free Alzheimer’s Association Helpline answers questions about memory loss, diagnosis and caregiving, day and night, in more than 200 languages (US).

If someone with dementia is missing

  1. STEP 115 minSearch close by firstCheck the house, garden, car and the places the person often walks to. Don’t spend longer than about 15 minutes.
  2. STEP 2911Then call for helpTell the operator the person has dementia and is a vulnerable adult. Police treat this as urgent.
  3. STEP 3PhotoHave details readyA recent photo, what they were wearing, medical conditions and places they used to live or work.

Based on Alzheimer’s Association guidance on wandering. Outside the US, call your local emergency number.